The Role of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide in Migraine Pathogenesis

Sokolov, Alexey Y.; Osipchuk, A. V.; Skiba, Ya. B.; Амелин, А. В.

doi:10.1134/s1819712422010123

Cited by 3 publications

(1 citation statement)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VIP is thought to be involved in thermoregulation, cell proliferation, immune response, smooth muscle tone, and nociception [ 32 , 73 ]. Among the complex scenarios of the trigeminovascular activation in the migraine attack, VIP seems to play an important role along with its homologous peptide PACAP [ 74 ]. VIP is released by parasympathetic fibers and exerts its role through the aforementioned receptors VPAC 1 and VPAC 2 , which show a similar affinity to VIP and PACAP.…”

Section: Metabotropic Receptors (G Protein-coupled Receptors)mentioning

confidence: 99%

Future targets for migraine treatment beyond CGRP

Al-Hassany¹,

Boucherie²,

Creeney³

et al. 2023

J Headache Pain

View full text Add to dashboard Cite

Background Migraine is a disabling and chronic neurovascular headache disorder. Trigeminal vascular activation and release of calcitonin gene-related peptide (CGRP) play a pivotal role in the pathogenesis of migraine. This knowledge has led to the development of CGRP(-receptor) therapies. Yet, a substantial proportion of patients do not respond to these treatments. Therefore, alternative targets for future therapies are warranted. The current narrative review provides a comprehensive overview of the pathophysiological role of these possible non-CGRP targets in migraine. Findings We covered targets of the metabotropic receptors (pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal peptide (VIP), amylin, and adrenomedullin), intracellular targets (nitric oxide (NO), phosphodiesterase-3 (PDE3) and -5 (PDE5)), and ion channels (potassium, calcium, transient receptor potential (TRP), and acid-sensing ion channels (ASIC)). The majority of non-CGRP targets were able to induce migraine-like attacks, except for (i) calcium channels, as it is not yet possible to directly target channels to elucidate their precise involvement in migraine; (ii) TRP channels, activation of which can induce non-migraine headache; and (iii) ASICs, as their potential in inducing migraine attacks has not been investigated thus far. Drugs that target its receptors exist for PACAP, NO, and the potassium, TRP, and ASIC channels. No selective drugs exist for the other targets, however, some existing (migraine) treatments appear to indirectly antagonize responses to amylin, adrenomedullin, and calcium channels. Drugs against PACAP, NO, potassium channels, TRP channels, and only a PAC1 antibody have been tested for migraine treatment, albeit with ambiguous results. Conclusion While current research on these non-CGRP drug targets has not yet led to the development of efficacious therapies, human provocation studies using these targets have provided valuable insight into underlying mechanisms of migraine headaches and auras. Further studies are needed on these alternative therapies in non-responders of CGRP(-receptor) targeted therapies with the ultimate aim to pave the way towards a headache-free future for all migraine patients.

show abstract

Section: Metabotropic Receptors (G Protein-coupled Receptors)mentioning

confidence: 99%

Future targets for migraine treatment beyond CGRP

Al-Hassany¹,

Boucherie²,

Creeney³

et al. 2023

J Headache Pain

View full text Add to dashboard Cite

show abstract

Neurophysiological and Vascular Mechanisms of Action of Serotoninergic Drugs for Abortive Migraine Treatment

Sokolov,

Skiba,

Lyubashina

2024

Neurosci Behav Physi

View full text Add to dashboard Cite

Neurophysiological and Vascular Mechanisms of Action of the Serotoninergic Drugs for Abortive Migraine Treatment

Sokolov,

Skiba,

Lyubashina

2023

Uspehi fiziologičeskih nauk

View full text Add to dashboard Cite

Abstract—Migraine is a form of primary headache that affects at least 10% of the world’s population. In addition to recommendations for modifying the patient’s lifestyle, migraine management involves stopping an attack that’s already occurred and/or preventing its occurrence. In the abortive treatment of this cephalalgia, both non-specific (eg, non-opioid analgesics) and specific pharmacological agents, can be used. The latter include, in particular, serotonergic drugs of the classes of triptans (selective 5-HT1B/1D receptor agonists), ditans (selective 5-HT1F-mimetics), and ergot alkaloids (non-selective modulators of various 5-HT receptor subtypes). The review discusses the currently availably results of numerous basic and applied studies of these drug groups, in which the neuronal and vascular components of their antimigraine pharmacodynamics were identified. A significant part of the information was obtained in vivo on the various experimental models of migraine based on the trigeminovascular theory of its pathogenesis. Other data are the results of ex vivo studies on isolated tissues and cell cultures. When analyzing these experimental results, evidence is provided in favor of similar mechanisms for realizing the antimigraine potential of all representatives belonging to the pharmacological classes listed, the neurotropic activity of which prevails over their direct intervention in vascular tone. At the same time, special attention is paid to the controversial and debatable issues in this area, the successful solution of which is a key to further progress in the pharmacotherapy of migraine.

show abstract

The Role of Pituitary Adenylate Cyclase-Activating Polypeptide and Vasoactive Intestinal Peptide in Migraine Pathogenesis

Cited by 3 publications

References 102 publications

Future targets for migraine treatment beyond CGRP

Future targets for migraine treatment beyond CGRP

Neurophysiological and Vascular Mechanisms of Action of Serotoninergic Drugs for Abortive Migraine Treatment

Neurophysiological and Vascular Mechanisms of Action of the Serotoninergic Drugs for Abortive Migraine Treatment

Contact Info

Product

Resources

About